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ABSTRACT
Lentiviral vectors almost universally use heterolo-
gous internal promoters to express transgenes. One
of the most commonly used promoter fragments is a
1.2-kb sequence from the human ubiquitin C (UBC)
gene, encompassing the promoter, some enhancers,
first exon, first intron and a small part of the second
exon of UBC. Because splicing can occur after tran-
scription of the vector genome during vector produc-
tion, we investigated whether the intron within the
UBC promoter fragment is faithfully transmitted to
target cells. Genetic analysis revealed that more than
80% of proviral forms lack the intron of the UBC pro-
moter. The human elongation factor 1 alpha (EEF1A1)
promoter fragment intron was not lost during lentivi-
ral packaging, and this difference between the UBC
and EEF1A1 promoter introns was conferred by pro-
moter exonic sequences. UBC promoter intron loss
caused a 4-fold reduction in transgene expression.
Movement of the expression cassette to the oppo-
site strand prevented intron loss and restored full
expression. This increase in expression was mostly
due to non-classical enhancer activity within the in-
tron, and movement of putative intronic enhancer se-
quences to multiple promoter-proximal sites actually
repressed expression. Reversal of the UBC promoter
also prevented intron loss and restored full expres-
sion in bidirectional lentiviral vectors.
INTRODUCTION
The HIV-1-based lentiviral vector (LV) is one of the most
common tools used for genetic modifications in biological
experiments and in gene therapy. Most LVs used are self-
inactivating, meaning that the region within the long termi-
nal repeat containing the promoter and enhancers has been
removed (1). In order to express a transgene within such
a vector, a promoter must therefore be placed within the
vector payload along with the transgene. Typically, in or-
der to express a protein-coding gene, a heterologous RNA
Pol II viral or cellular promoter will be used, and common
examples are viral promoters from cytomegalovirus, murine
leukaemia virus, and spleen focus-forming virus, and cellu-
lar promoters fromhuman genes such as elongation factor 1
alpha (EEF1A1), ubiquitin C (UBC) and phosphoglycerate
kinase (PGK1) (2,3).
During the viral production process, RNA Pol II tran-
scribes the vector genome, typically from a transfer plas-
mid that has been transfected into the producer cells. Vir-
tually all systems incorporate the Rev protein from HIV-1,
which binds to the Rev response element (RRE) within the
HIV-1 genome and mediates splicing-independent nuclear
export of the viral genome. Despite the incorporation of the
RRE sequence into LV constructs, however, introns within
the vector payload can be lost during packaging if the splic-
ing event retains the packaging signal (Psi) in the transcript.
With some expression cassettes, though, such as one includ-
ing the intron-containing promoter of EEF1A1 and one
containing the hybrid CAG promoter, intron loss has not
been observed during lentiviral packaging (4,5). From these
observations, it has sometimes been inferred that lentiviral
gene transfer allows for the transmission of introns (6).
We set out to investigate whether the intron contained by
the human UBC promoter is faithfully transmitted from a
transfer plasmid through to proviral forms in stably trans-
duced cells. We hypothesized that a loss of the UBC intron
would result in a significant reduction in transgene expres-
sion, as the UBC intron has been reported to possess strong
enhancer activity (7). In contrast to previous findings with
the EEF1A1 intron, the UBC intron was found to be miss-
ing in themajority of proviral forms in cells transducedwith
vector produced from intron-containing plasmids. The lack
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of the UBC intron resulted in a roughly 2-fold decrease in
expression in both transient transfection and stable trans-
duction experiments in cell lines, and a 4-fold decrease in
transduction experiments in primary cells. This contrasted
strikingly with experiments with the EEF1A1 promoter, in
which the majority of proviral forms maintained the in-
tron.Reversal of theUBC expression cassette prevented this
splicing-mediated intron loss and maximized expression in
uni- and bidirectional LVs. The difference in intron mainte-
nance between the UBC and EEF1A1 promoters is caused
by promoter exonic sequences, rather than the intronic se-
quences themselves.
MATERIALS AND METHODS
Plasmid construction
All plasmid sequences used in these studies are included as
Supplementary files, available at NAR online.
The human ubiquitin C promoter was amplified via
polymerase chain reaction (PCR) from FUGW (8), phos-
phorylated with T4 polynucleotide kinase and ligated into
linearized and blunted pCafe (Cassette for expression)
to generate pCafe-UBC. The woodchuck hepatitis virus
post-transcriptional regulatory element sequence (herein
‘PRE,’ referred to as ‘LPRE’ in Schambach et al.) was
PCR amplified and cloned into pCafe-UBC linearized with
KpnI using In-Fusion (Clontech Laboratories, Mountain
View, CA, USA, Cat. No. 639645). The Emerald vari-
ant of EGFP was PCR amplified from pRSET-EmGFP
(Life Technologies, Carlsbad, CA, USA, Cat. No. V353-20)
and cloned into HpaI-linearized pCafe-UBC-PRE using
In-Fusion to generate pCafe-UBC-EmGFP-PRE. pCafe-
UBCs-EmGFP-PRE was generated in a similar fashion,
with UBC cloning primers designed to omit the UBC in-
tron sequence.
For the expression cassettes in the reverse orientation
(ro) plasmids, pCafe-roUBC-EmGFP-bGHpA and pCafe-
roUBCs-EmGFP-bGHpA, the bovine growth hormone
polyadenylation signal (bGHpA) was PCR amplified from
pcDNA4/HisMaxA (Life Technologies, Cat. No. V864-20)
and inserted after the transgene.
For constructs with the UBC intron repositioned
(i), pCafe-iUBC-EmGFP-PRE, pCafe-roiUBC-EmGFP-
PRE and pCafe-rofiUBC-EmGFP-PRE, UBC intronic se-
quences were PCR amplified from pCafe-UBC-PRE and
cloned into EcoRV-linearized pCafe-UBCs-EmGFP-PRE
using In-Fusion.
For a construct with the UBC enhancer deleted (dEnh),
pCafe-dEnhUBC-EmGFP-PRE, pCafe-UBC-EmGFP-
PREwas PCR amplified using overlapping, outward-facing
primers flanking the putative intronic enhancer region and
recircularized with In-Fusion after DpnI treatment.
For all pCCLc (3) LVs, expression cassettes were removed
from pCafe plasmids with EcoRV/KpnI digestion and lig-
ated into EcoRV/KpnI-linearized pCCLc with the NEB
Quick Ligase Kit (New England Biolabs, Ipswitch, MA,
USA).
The bidirectional (BD) vector was constructed by as-
sembly of PCR amplicons of the human growth hor-
mone polyadenylation signal (hGHpA) and bidirectional
mCMV/UBC promoter (9) and EGFP and WPRE from
FUGW, andmCherry fromEFS-single-IDLV (10) designed
with overlapping homology with the pCCLc backbone us-
ing In-Fusion. roBD vector was constructed by restriction
digest of BD to invert the mCherry-bidirectional promoter-
EGFP cassette between inverse hGHpA and WPRE, and
ligated with the NEB Quick Ligase Kit.
Cell culture
D10mediumwas prepared by adding 50ml heat-inactivated
foetal bovine serum (Gemini Bio-Products, West Sacra-
mento, CA, USA, Cat. No. 900-208) and 5.5 ml 100X L-
Glutamine:Penicillin:Streptomycin solution (Gemini Bio-
Products Cat. No. 400-110) to 500 ml Dulbecco’s modified
Eagle’s medium without L-glutamine (Mediatech, Hern-
don, VA,USA, Cat. No. 15-013-CV). R10mediumwas pre-
pared by adding the same two components to 500 ml RPMI
1640mediumwithout L-glutamine (MediatechCat. No. 15-
040). HEK293T cells, hereafter ‘293T,’ (ATCC, Manassas,
VA, USA, Cat. No. CRL-1268) were maintained in D10
medium, and K562 (ATCC Cat. No. CCL-243) cells were
maintained in R10 medium.
Vector production
LV supernatant was produced by transfection of 1 ×
107 293T cells with 10 g pCMVR8.91 (11), 10 g of
the appropriate pCCLc vector plasmid and 2 g pCAG-
VSV-G (12). Transfection mixtures were prepared in 1.5
ml DPBS by adding the plasmids and 66 l 1 mg/ml
branched PEI solution (Sigma-Aldrich, St. Louis, MO,
USA, Cat. No. 408727-100ML), and then vortexing for sev-
eral seconds. After incubation at room temperature for 5–
10 min, transfection mixes were added dropwise to 293T
cells plated 24 h earlier in 10 cm dishes. After ∼16 h, the
mediumwas changed to UltraCULTUREmedium (Lonza,
Basel, Switzerland, Cat. No. 12-725F) supplemented with
50 U/ml penicillin, 50 g/ml streptomycin, 2 mM L-
glutamine and 20 mM HEPES. Viral supernatant was har-
vested 24–48 h after this medium change.
For roUBC vectors, 5 g pcDNA3-NovB2 was included
to prevent a drop in titers caused by the presence of tran-
scripts antisense to the vector genomic RNA (13). An addi-
tional 15l 1g/ml PEI solution was added to compensate
for the increased plasmid DNA.
Vector was concentrated ∼150-fold by ultracentrifuga-
tion at 26,000 rpm for 90 min at 4◦C in a Beckman Coulter
SW-32Ti rotor for transduction of human CD34+ HSPCs.
Transfection
293T cells were seeded at 8 × 105 cells/well in 6-well
plates (Corning, Corning, NY, USA, Cat. No. 3516) in D10
medium. Twenty-four hours later, 1.5 g of plasmid was
prepared for transfection in 200 l Opti-MEM I medium
(Life Technologies, Carlsbad, CA, USA, Cat. No. 31985-
062) in 1.5 ml microcentrifuge tubes, 4.5 l of TransIT-293
transfection reagent (Mirus Bio, Madison, WI, USA, Cat.
No. MIR 2700) was added, and the mixtures were vortexed
briefly and incubated at room temperature for 5 min before
being added dropwise to the cells. Cells were collected 48
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h after transfection by brief trypsinization and analyzed for
green fluorescent protein reporter expression on a BDLSR-
Fortessa flow cytometer.
Transduction
For lentiviral expression analysis, K562 cells were plated in
24-well plates at 5 × 104 cells/well and treated with a range
of vector doses to obtain populations with 10% transduc-
tion or lower, thus ensuring that the majority of cells re-
ceived only single integrations. Cells were cultured for 1–
2 weeks before flow cytometric analysis to dilute out non-
integrated vector and to allow fluorescent protein levels to
reach steady state.
For expression analysis in primary human CD34+
HSPCs from mobilized peripheral blood, cryopreserved
cells were thawed and prestimulated overnight in X-VIVO
15 medium (Lonza) supplemented with 50 ng/ml human
fms-like tyrosine kinase 3 (FLT-3) ligand, 50 ng/ml hu-
man stem cell factor and 50 ng/ml human thrombopoietin
(PeproTech, Rocky Hill, NJ, USA). Viral vector was then
added in an equal volume of the same medium to achieve a
final vector concentration of 3 × 105 transducing units/ml,
as determined by transduction of K562 cells. This vector
dose yielded ∼10% transduction. Twenty-four hours after
vector addition, 2ml ofmyeloid differentiationmediumwas
added, composed of IMDM supplemented with 20% foetal
bovine serum, 0.5% bovine serum albumin, 5 ng/ml human
interleukin-3, 10 ng/ml human interleukin-6 and 25 ng/ml
human stem cell factor (PeproTech).
PCR analysis of splicing
Genomic DNA from transduced K562 cells was analyzed
via PCR using KAPA HiFi Hot Start polymerase and
primers UBC intron F (AAGTAGTCCCTTCTCGGC-
GAT), UBC intron R (GGTCAGCTTGCCGTAGGT),
EEF1A1 intron F (GTTCTTTTTCGCAACGGGTTTG)
and EEF1A1 intron R (TGTGGCCGTTTACGTCGC).
Quantitative droplet digital PCR (ddPCR) was car-
ried out by analysis of genomic DNA from UBC
vector-transduced K562 cells using primers UBCint F
(GGCGAGTGTGTTTTGTGAAGTTT) and EmGFP R
(TACGTCGCCGTCCAGCTC), and probe FAM-EmGFP
(FAM-CACCACCCCGGTGAACAGCTCCTCG). For
EEF1A1 vector analysis, the UBCint F primer was
substituted with EEF1A1int F (TCTCAAGCCTCA-
GACAGTGGT). The spliced form of UBC was quantified
using UBCs F (GCTGTGATCGTCACTTGACA) instead
of UBCint F. ddPCR was carried out according to the
manufacturer’s instructions, using 100 ng of template
gDNA. One unit of DraI enzyme (New England Biolabs)
was added to the ddPCR master mix containing ddPCR
Supermix for Probes (Bio-Rad, Hercules, CA, USA), and
predigestion was carried out in the PCR reaction mixes
for 1–2 h at 37◦C before droplet generation and thermal
cycling.
For analysis of vector genomes in vector supernatant,
RNA was purified from 500 l of raw vector supernatant
using the PureLink RNAMini Kit liquid sample procedure
(Life Technologies). Reverse transcription was carried out
before PCR using iScript cDNA Synthesis Kit (Bio-Rad).
UBC
roUBC
roUBCs
UBCs
iUBC
roiUBC
ro UBC
dEnhUBC
EmGFP
EmGFP
EmGFP
EmGFP
EmGFP
EmGFP
EmGFP
promoter + exon 1 intron 1 + exon 2 (partial)
putative enhancer region
ψ SIN LTRASDSSIN LTR
expression cassette
EmGFP
Figure 1. Expression vectors used for studies. Lentiviral diagram depicts
location in CCLc vectors. roUBC and roUBCs vectors contain a bovine
growth hormone polyadenylation signal (not depicted), in the proper re-
verse orientation, after the end of the EmGFP reading frame. pCafe
expression plasmids contained identical cassettes upstream of an SV40
polyadenylation signal.
Luciferase assay
pGL4.25 vector (Promega, Madison, WI, USA) contain-
ing an optimized luciferase open reading frame driven by
a minimal TATA-box promoter was used to assay for en-
hancer activity of the UBC and EEF1A1 introns. A pro-
moterless enhancer sequence from the CMV promoter was
used as a positive control. All inserts were cloned via PCR
and Gibson assembly into pGL4.25 linearized with EcoRV
and KpnI. All plasmid sequences are provided as Supple-
mentary data. Luciferase assays were performed in 293T
cells plated on 96-well tissue culture-treated plates. 5 × 104
cells per well were plated in D10 medium, and 18 h later,
transfection mixes were prepared in OPTI-MEM with 100
ng reporter plasmid and 0.3 l TransIT-293 per well. Sam-
ples were prepared 48 h after transfection with the Dual-
Luciferase Reporter Assay System (Promega) and lumines-
cence readings were takenwith a Tecan InfiniteM1000 PRO
plate reader (Tecan, Ma¨nnedorf, Switzerland).
RESULTS
UBC intron is missing from proviral forms, and expression
cassette reversal prevents loss
To assess whether UBC intron 1 is maintained during pack-
aging, pCCLc LV DNA constructs and simpler pCafe ex-
pression plasmid constructs for transient transfection were
created with various modifications of the UBC promoter
(Figure 1). All constructs contained the Emerald variant of
green fluorescent protein (EmGFP), which allowed for ex-
pression analysis via flow cytometry (14). UBC constructs
contained the full UBC promoter fragment, as it exists in
the human genome, whereas shorter UBCs constructs were
designed with a full deletion of UBC intron 1, which would
be the expected proviral form if canonical splicing occurred
during packaging. To test whether movement of the expres-
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Figure 2. Genetic analysis of UBC splicing. (A) PCR strategy with primer
locations and expected product sizes. (B) Electrophoresis of PCR prod-
ucts from controls and gDNA from cells transduced with lentiviral vectors
bearing UBC promoter variants.
sion cassette to the opposite strand would avoid splicing-
mediated loss of the intron, reverse orientation (ro) con-
structs roUBC and roUBCs were created by reversing the
promoter and transgene and inserting a polyadenylation
signal after the transgene. Importantly, while the payloads
of the pCCLc LVs pass through an RNA intermediate stage
and are susceptible to splicing-mediated loss, payloads of
the pCafe expression plasmids have no RNA intermediate
and therefore cannot lose genetic elements due to splicing.
Viral vectors were produced in 293T cells and used to
transduce K562 cells for PCR-based genetic analysis of
proviral forms (Figure 2A). PCR analysis of gDNA two
weeks post-transduction revealed that many CCLc-UBC-
EmGFP-PRE proviral forms contained an amplicon con-
sistent with intron loss, as indicated by analysis of UBCs
proviral forms (Figure 2B, lanes 5 and 6). Sanger sequenc-
ing of the short product confirmed that the expected canon-
ical splicing had occurred (data not shown). In contrast,
roUBC proviral forms yielded no truncated PCR product,
suggesting that reversal of the expression cassette fully pre-
vented intron loss (Figure 2B, lane 7). Because of the signif-
icant difference in predicted PCR product size between the
intron-containing templates and intron-lacking templates,
there could be a substantial bias toward amplification of the
intron-lacking templates and overestimation of the amount
of intron loss from this result. Therefore, to quantify the
frequency of intron loss, a duplex digital PCR assay was set
up in which the signal from a primer and probe set spanning
the intron and EmGFP transgene was normalized using a
primer and probe set to the LV packaging signal (Figure 3A
and B). This analysis showed that only 18% of UBC vector
forms retained the UBC intron (Figure 3C), while roUBC
vector forms fully retained the intron.
In order to assess whether events during transduction and
reverse transcription influenced the proportion of provi-
ral forms containing introns, we collected RNA from UBC
viral supernatants and quantified the fraction of RNA
genomes containing spliced UBC introns. We then com-
pared this to the fraction of vector proviral forms contain-
ing spliced introns in K562 cells transduced with the same
supernatants. These values agreed very closely, suggesting
that the introns were already missing in vector particles and
were therefore removed in the packaging cells (Supplemen-
tary Figure S1).
Loss of intron lowers expression from UBC promoter
To assess the effect of intron loss on transgene expression,
pCafe expression plasmids containing the full UBC pro-
moter element or the truncated UBCs promoter with the
intron region deleted were transiently transfected into 293T
cells and analyzed at 48 h post-transfection via flow cytom-
etry. TheUBC promoter yielded significantly higher expres-
sion than the UBCs promoter, by a margin of ∼2-fold (Fig-
ure 4A). A similar 2-fold difference was observed between
the roUBC and roUBCs constructs. Because these plasmids
were transfected directly into cells, no intron loss was pos-
sible, and the UBC promoter plasmid molecules assayed
therefore all contained the intron.
Having established that the presence of the intron confers
higher expression in these transfection experiments where
intron loss was not possible, we next examined expression
from the various constructs packaged as LVs 2 weeks af-
ter transduction of K562 cells. As the genetic analysis re-
vealed that the majority of UBC LV forms lack the in-
tron, we reasoned that the UBC vector would express levels
of EmGFP similar to the UBCs vector. Indeed, the fluo-
rescence of EmGFP-expressing cells in populations trans-
duced with the UBC vector was nearly equivalent to that in
populations transduced with UBCs vector (Figure 4B). In
contrast, the roUBC vector showed ∼2-fold higher fluores-
cence in cells than the UBC vector, consistent with the ge-
netic analysis indicating that the roUBC vector retains the
intron.
We also transduced human CD34+ hematopoietic stem
and progenitor cells enriched from the peripheral blood of
a healthy donor treated with granulocyte-colony stimulat-
ing factor to determine if the improved expression from
the roUBC vector compared to the UBC vector would also
be observed in a primary cell type relevant to lentiviral
gene therapy. After 10 days of culture post-transduction
in myeloid differentiation conditions, cells transduced with
roUBC vector showed 4-fold higher expression than cells
transduced with UBC (Supplementary Figure S2). Genetic
analysis showed that intron loss was similar in the UBC-
transduced cells to that observed in K562 cells and that
the intron was fully maintained in roUBC-transduced cells
(Supplementary Figure S3).
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Figure 3. Quantitative analysis of UBC intron loss during packaging and transduction. (A) Duplex ddPCR strategy for quantifying UBC intron copies
(FAM-UBC intron), normalized to total proviral integrations (HEX-LV psi). (B) Representative raw data from ddPCR, illustrating separation between
positive and negative droplets. (C) Ratio of UBC intron copies to total proviral copies in controls and samples transduced with LV bearing UBC promoter
variants. Error bars represent 95% confidence interval based on ddPCR Poisson statistics.
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Positive effect of UBC intron on expression is not through
classical enhancer activity
Aside from reversal of the expression cassette, we also
sought other ways to retain full expression of the UBC
promoter fragment in an LV. We first investigated whether
movement of the reported intronic enhancer sequence to
a site immediately upstream of the promoter would lead
to equivalent expression compared to the full-length UBC
promoter fragment (7). Importantly, this variant lacked the
intronic splice sites, which should allow its transmission
in LVs. However, the resulting iUBC construct performed
worse than UBCs (Figure 4C). roiUBC and rofiUBC were
created and analyzed to assess whether the orientation of
the enhancer sequence relative to the promoter was impor-
tant, but these promoter variants expressed no better than
iUBC (Figure 4C). We finally constructed dEnhUBC, in
which the putative enhancer sequence was deleted, but the
splicing sites were retained. This variant expressed slightly
more EmGFP thanUBCs, presumably due to improved nu-
clear export from splicing, but significantly less than UBC
(Figure 4C). These results are consistent with a follow-up
study on the UBC promoter fragment intron, which found
that its enhancer activity was fully dependent on its posi-
tion within the intron (15). This behavior, termed intron-
mediated enhancement, is poorly understood.
We reasoned that if the UBC intron sequence were not
a classical enhancer, then it should not increase expression
from a heterologous minimal promoter. Indeed, when the
intron sequence was placed in a luciferase reporter plas-
mid upstream of a minimal promoter in a forward or re-
verse orientation, no increase in luciferase expression over
backgroundwas observed, in contrast to a plasmid in which
a CMV enhancer sequence was placed upstream (Supple-
mentary Figure S4). In fact, expression from these plasmids
was significantly lower than fromplasmidswith theminimal
promoter alone, consistent with the UBC intron sequence
being repressive when placed outside the transcription unit.
This repressive effect mirrors the reduction in expression
seen when intronic sequences were placed upstream of the
UBCs promoter form (Figure 4C). Interestingly, the same
was true for EEF1A1 intron 1 in forward or reverse orien-
tation (Supplementary Figure S4).
EEF1A1 intron is maintained in proviral forms and aids in
maximal expression
Because the observation of intron loss from the UBC pro-
moter contrasts so starkly with reports on the EEF1A1
promoter fragment in LVs, we created expression vectors
for transient transfection and lentiviral production with
the EEF1A1 promoter fragment and an EmGFP reporter.
PCR and ddPCR analysis of gDNA from transduced cells
showed that nearly all vector forms retained the intron
within the promoter (Figure 5B, lane 5). Extreme contrast
adjustment of the gel electrophoresis image can reveal a
barely detectable amount of short product at the length
expected upon intron loss, but quantitative ddPCR analy-
sis does not detect this small population of intron-lacking
proviral forms (Figure 5C). Consistent with these observa-
tions and with a previous report (2), a ∼2-fold difference
in expression between the intron-containing and intron-
lacking promoters was observed both in transient transfec-
tion (Figure 5D) and transduction (Figure 5E) experiments,
suggesting that the EEF1A1 promoter element’s intron is
indeed being faithfully transmitted in almost all cases.
Difference in intron transmission is determined by promoter
exon sequences
We hypothesized that the difference in intron retention be-
tween the UBC and EEF1A1 promoters was due to se-
quence determinants of splicing efficiency or splicing kinet-
ics within the introns. To test this, we swapped the introns
fromone promoter to the other, creatingUBC (EEF1A1int)
and EEF1A1(UBCint) vectors. Surprisingly, we found that
the UBC (EEF1A1int) LV lost the EEF1A1 intron and ex-
pressed similar levels of EmGFP to the intronless UBCs
vector, while the EEF1A1(UBCint) maintained the UBC
intron and expressed significantly more EmGFP than the
intronless EEF1A1s vector (Supplementary Figure S5).
These results suggest that the distinct exon sequences of the
two promoters are determining whether the introns are re-
tained during lentiviral production.
Expression cassette modification maximizes expression from
UBC bidirectional vectors
We finally sought to improve expression from UBC
promoter-based bidirectional vectors mediating coordi-
nated expression of two transgenes in LVs (9,16). Because
the vector design calls for a sense-strand orientation of the
UBC promoter, we reasoned that the majority of proviral
forms would lose the UBC intron and that reversal of the
dual, divergent UBC and minimal cytomegalovirus (CMV)
promoters would lead to increased expression due to intron
inclusion with the UBC-promoted transgene (Figure 6A).
Genetic analysis of stably transduced 293T cells revealed
that the UBC intron was lost 75% of the time from BD
vectors, in which the UBC promoter is on the vector sense
strand, whereas in roBD vectors, nearly all of the proviral
forms contained the UBC intron (Figure 6B). This led to an
increase in EGFP expression driven by the UBC promoter
in stably transduced cells (Figure 6C). Surprisingly, in light
of the expression data suggesting that the intron does not
contain a traditional enhancer, mCherry expression driven
by the minimal CMV promoter was also increased in re-
tained UBC intron in roBD-transduced cells.
DISCUSSION
Lentiviral gene transfer has recently advanced into clinical
gene therapy trials, with multiple successes and no clinically
significant adverse events, and has also shown promise in
many pre-clinical studies (17–22). As therapies are devel-
oped for additional disorders, new vectors will be created
bearing various genomic fragments for transgene regula-
tion. Past promoter/transgene combinations have required
the presence of introns for full activity and regulation, and
it is likely that some future designs will require them as well.
Our results suggest that introns differ in terms of their
likelihood of loss during vector production and transduc-
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Figure 5. EEF1A1 analysis. (A) Diagrams of lentiviral vectors bearing EEF1A1 promoter variants. (B) Gel electrophoresis of PCR product amplifying
across EEF1A1 intron in stably transduced K562 cells, greater than 2 weeks post-transduction. (C) ddPCR quantification of the ratio of intron copies
to proviral copies in samples analyzed in (B). Error bars represent 95% confidence interval. (D) gMFI of transiently transfected 293T cells 48 h post-
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gMFI of stably transduced K562 cells 10 days post-transduction, measured by flow cytometry.
tion. While the human UBC promoter fragment was miss-
ing its intron in most proviral forms, the human EEF1A1
promoter fragment was not similarly affected. Inclusion
of the UBC intron requires that the transgene cassette
be reversed to avoid the processing of splicing machin-
ery, but the EEF1A1 intron is maintained in almost ev-
ery proviral form even though it is theoretically exposed
to the spliceosome. A previous study indicates that the hy-
brid CAG promoter is also maintained throughout vector
production and transduction (4). An intronless version of
the EEF1A1 promoter has moved into clinical trials for
both adenosine-deaminase-deficient severe combined im-
munodeficiency (ADA-SCID) and X-linked SCID (SCID-
X1), and preclinical studies suggested that it will drive suf-
ficient transgene expression for therapeutic effect. Our data
indicate that a full EEF1A1 promoter containing intron 1
leads to roughly 2-fold higher transgene expression, an in-
crease that could be necessary or beneficial for future vector
designs. Overall, these results illustrate the importance of
full genetic characterization of retroviral vectors, as known
or unknown introns can lead to transduced cells bearing
highly variant vector forms. In the area of gene therapy,
where product characterization is important from a regula-
tory standpoint, this variation is unlikely to find acceptance.
It has been reported that antisense RNA targeted to
splice donor or acceptor sites can prevent splicing of pri-
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mary transcripts (23). We therefore attempted to inhibit
splicing of UBC vector genomes using U6-driven plasmids
expressing 50 nt antisense sequences to either the splice
donor or splice acceptor site during lentiviral production.
Unfortunately, these constructs did not lead to higher ex-
pression from UBC vectors upon transduction when used
alone or in combination (data not shown). It is possible that
this strategy could lead to retention of other introns in LVs,
but it was ineffective for the UBC intron in our experiments.
We found that the UBC promoter intron does indeed
increase expression, as previously reported, but that the
enhancer-like activity within the intron sequence is depen-
dent on its location inside the intron. This could be paral-
leled by future vector designs incorporating transgenes with
endogenous introns for full activity, in which regulatory ac-
tivity of intronic sequences might similarly not be mobile.
Further research is also warranted to investigate why the
UBC intronic sequences have a positive effect on expres-
sion when present within the transcription unit, but a neg-
ative effect when placed upstream of the promoter. This
would likely have important implications for both endoge-
nous gene regulation and transgene regulation for gene ther-
apy and genetic engineering. Importantly, our data suggest
that such introns are relatively safe payloads for integrating
vectors, as they probably will not transactivate nearby pro-
moters in the manner that has caused adverse events and
subclinical clonal expansion in clinical gene therapy trials
(18,24–27).
The UBC intron and EEF1A1 intron 1 do not differ no-
ticeably at the sequence level in terms of their adherence
to canonical splice donor, acceptor and branch point sites,
and our data from vectors in which the introns are swapped
indicate that the sequence determinants of intron loss are
not within the introns themselves but within the exonic se-
quences of the UBC and EEF1A1 promoters. This would
be unfortunate if true generally, as potential modifications
to vectors to alter splicing would be limited dramatically
in the majority of exons that are coding sequences. Biolog-
ically speaking, it is unsurprising, as exons in the human
genome are known to contain exonic splicing enhancers
as well as exonic splicing suppressors/silencers. These se-
quences control the efficiency of splicing of human introns,
most of which are thought to be suboptimally defined (28).
We hypothesize that the difference in frequency of loss
between these introns is linked to the speed at which they
are spliced, which can be largely determined by exonic se-
quences. Future experiments could assess the splicing kinet-
ics of these two genetic elements, the speed of which would
be predicted to correlate inversely with intron transmission.
While new work has examined the kinetics of transcript
splicing and release from chromatin, the sequence deter-
minants of the range of rates observed for different tran-
scripts are not yet understood (29). A better understand-
ing of the determinants of splicing kinetics could direct the
modification of the UBC promoter fragment to decrease
splicing speed sufficiently to get intron-containing genomic
RNA into vector particles, while maintaining efficient splic-
ing during transgene expression.
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